https://doctransparency.com/doctor/tx/dallas/daragh-heitzman-1023083961
Medicare Enrolled

Dr. Daragh Heitzman, M.D.

Neurology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
6080 N CENTRAL EXPY STE 100, Dallas, TX 75206
2148273610
In practice since 2006 (20 years)
NPI: 1023083961 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Heitzman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Heitzman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Heitzman

Dr. Daragh Heitzman is a neurology in Dallas, TX, with 20 years in practice. Based on federal Medicare data, Dr. Heitzman performed 13,243 Medicare services across 797 unique beneficiaries.

Between the years covered by Open Payments, Dr. Heitzman received a total of $32,842 from 70 pharmaceutical and/or device companies across 817 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Heitzman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 7% volume in TX$ $32,842 industry payments

Medicare Practice Summary

Medicare Utilization ↗
13,243
Medicare services
Top 7% in TX for neurology
797
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~662 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
MRI contrast dye injection (gadoterate)12,080$0$1
Office visit, established patient, complex (40-54 min)419$124$440
Test to measure expiratory airflow and volume107$18$85
Needle measurement of electrical activity in arm or leg muscles, complete study100$77$104
New patient office visit, complex (60-74 min)81$157$626
Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle52$62$165
Mri scan of brain before and after contrast51$166$1,530
Needle measurement of electrical activity in arm or leg muscles, limited study50$50$67
Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box48$160$580
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or42$25$100
Nerve conduction, 11-12 studies41$191$800
Office visit, established patient (30-39 min)39$94$355
Needle measurement of electrical activity in trunk or head muscles28$65$96
Mri scan of blood vessels of head without contrast20$85$1,225
Nerve conduction, 13 or more studies19$223$915
Mri scan of lower spinal canal without contrast15$90$990
Measurement of brain wave activity (eeg), awake and drowsy15$306$1,110
Mri scan of blood vessels of neck before and after contrast13$222$1,930
Mri scan of upper spinal canal without contrast12$65$975
Office visit, established patient (20-29 min)11$72$225
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$32,842
Total received (2018-2024)
Avg $4,692/year across 7 years
Top 12% in TX for neurology
70
Companies
817
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$15,419 (46.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,849 (42.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,575 (10.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,443
2023
$12,324
2022
$3,604
2021
$3,721
2020
$641
2019
$1,932
2018
$7,177

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amylyx Pharmaceuticals, Inc.
$10,337
Merz North America, Inc.
$5,042
MITSUBISHI TANABE PHARMA AMERICA, INC.
$3,575
Genentech USA, Inc.
$963
UCB, Inc.
$813
Sunovion Pharmaceuticals Inc.
$788
Biogen, Inc.
$761
ABBVIE INC.
$716
Alexion Pharmaceuticals, Inc.
$702
GENZYME CORPORATION
$550
Allergan Inc.
$517
Novartis Pharmaceuticals Corporation
$516
Teva Pharmaceuticals USA, Inc.
$506
ARGENX US, INC.
$492
PFIZER INC.
$466
Lilly USA, LLC
$384
Avanir Pharmaceuticals, Inc.
$355
Celgene Corporation
$322
Merz Pharmaceuticals, LLC
$297
Janssen Pharmaceuticals, Inc
$285
Amgen Inc.
$272
ACADIA Pharmaceuticals Inc
$257
Lundbeck LLC
$255
Eisai Inc.
$237
Neurocrine Biosciences, Inc.
$236
EMD Serono, Inc.
$224
Takeda Pharmaceuticals U.S.A., Inc.
$219
Ipsen Biopharmaceuticals, Inc
$209
McKesson Specialty Care Distribution, LLC
$203
SK Life Science, Inc.
$170
Acorda Therapeutics, Inc
$161
AbbVie Inc.
$150
Allergan, Inc.
$134
Amneal Pharmaceuticals LLC
$130
Biohaven Pharmaceuticals, Inc.
$114
Grifols USA, LLC
$109
Biohaven Pharmaceutical Holding Company Ltd.
$107
Mitsubishi Tanabe Pharma America, Inc.
$99
Upsher-Smith Laboratories LLC
$86
Horizon Therapeutics plc
$85
CSL Behring
$81
Avion Pharmaceuticals
$66
Adamas Pharmaceuticals, Inc.
$61
Alnylam Pharmaceuticals Inc.
$61
Bayer HealthCare Pharmaceuticals Inc.
$55
TG Therapeutics, Inc.
$53
AbbVie, Inc.
$50
Corium, LLC
$49
CATALYST PHARMACEUTICALS, INC.
$41
Neurelis, Inc.
$39
Avadel CNS Pharmaceuticals, LLC
$34
TG THERAPEUTICS, INC.
$32
Mallinckrodt LLC
$32
Otsuka America Pharmaceutical, Inc.
$32
UPSHER-SMITH LABORATORIES LLC
$31
Tactile Systems Technology Inc
$29
Greenwich Biosciences, Inc.
$28
Kyowa Kirin, Inc.
$27
Harmony Biosciences Llc
$24
Octapharma USA, Inc.
$21
Boston Scientific Corporation
$19
Philips Electronics North America Corporation
$18
Medtronic USA, Inc.
$17
Assertio Therapeutics, Inc.
$17
BOSTON SCIENTIFIC CORPORATION
$15
GE HEALTHCARE
$15
IDORSIA PHARMACEUTICALS US INC
$14
Catalyst Pharmaceuticals, Inc.
$13
HOSPIRA, INC.
$13
HARMONY BIOSCIENCES LLC
$13
Top 3 companies account for 57.7% of total payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · Adlarity · Aimovig · Austedo XR · BOTOX · BOTOX THERAPEUTIC · BRIUMVI · Betaseron · Briviact · CAMBIA · COMIRNATY · COPAXONE · DAYBUE · DUOPA · DYSPORT · Dhivy · Duopa · Dysport · EMGALITY · Enspryng · Epidiolex · Evrysdi · FABRY-DISEASE · FIRDAPSE · Flexitouch Plus · Fycompa · GAMMAGARD · GILENYA · GOCOVRI · Gamunex-C · HYQVIA · Hizentra · INBRIJA · INGREZZA · KESIMPTA · KYNMOBI · LEADPOINT · LEMTRADA · LUMIZYME · LUMRYZ · LYRICA · Leqembi · MAYZENT · Mavenclad · NEXVIAZYME · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONPATTRO · Ocrevus · Ongentys · PANZYGA · PAXLOVID · POMPE - DISEASE · Ponvory · QUDEXY XR TOPIRAMATE EXTENDED RELEASE CAPSULES · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUVIVIQ · RADICAVA · RELYVRIO · REXULTI · RYTARY · Radicava · Rebif · Rystiggo · SOLIRIS · Skyclarys · Soliris · TECFIDERA · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TYSABRI · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VERCISE · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vercise · Vimpat · WAKIX · Wakix · XEOMIN · Xeomin · ZEPOSIA · Zinbryta · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (47%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $248 per 100 Medicare services performed
Looking for a neurology in Dallas?
Compare neurologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse neurologys nearby

Geographic Context

Neurologys within 10 mi
241
Per 100K population
9.3
County median income
$74,149
Nearest hospital
BAYLOR SCOTT AND WHITE MEDICAL CENTER UPTOWN
2.3 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Heitzman is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and high industry engagement (speaking/promotional, top 12%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Heitzman experienced with mri contrast dye injection (gadoterate)?
Based on Medicare claims data, Dr. Heitzman performed 12,080 mri contrast dye injection (gadoterate) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Heitzman receive payments from pharmaceutical companies?
Yes. Dr. Heitzman received a total of $32,842 from 70 companies across 817 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Heitzman's costs compare to other neurologys in Dallas?
Dr. Heitzman's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Heitzman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →